Linaclotide Delayed Release via Enteric Coating

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current formulations of linaclotide for treating gastrointestinal disorders suffer from chemical instability due to moisture-induced degradation, making it challenging to develop stable and effective delayed release compositions that target the lower gastrointestinal tract.

Innovation Solution

The development of stable, solid, oral dosage forms of linaclotide that exhibit delayed release in the lower gastrointestinal tract, utilizing enteric-coated beads or tablets with pH-sensitive polymeric coatings, and incorporating stabilizing agents such as sterically hindered primary amines, cations, and polymers to enhance stability and targeted release.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If immediate release formulation is used, then linaclotide is released throughout the GI tract, but excess fluid secretion occurs in upper GI tract causing diarrhea

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddiarrhea

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The formulation segments the release location of linaclotide by using enteric-coated beads that prevent release in the upper GI tract and enable targeted release only in the distal colon, thereby eliminating harmful fluid secretion in the upper tract while maintaining therapeutic efficacy

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

An enteric coating polymer acts as an intermediary barrier that prevents linaclotide from interacting with the upper GI tract environment, allowing the drug to pass through unchanged and release only when encountering the specific pH conditions of the distal colon

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If enteric coating is applied to achieve delayed release, then targeted delivery to lower GI is improved, but chemical instability due to moisture remains

Engineering Contradiction:

Improvetargeted releaseVSAvoidchemical stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The formulation uses a nested structure where linaclotide is embedded within enteric-coated beads, which are then enclosed in a capsule. This nested arrangement provides multiple protective layers that shield linaclotide from moisture while enabling controlled release in the distal colon

Inventive Principle:

Principle #7Nested doll (Nesting)

Solution Approach 2:

Enteric coating polymers form flexible thin film barriers around linaclotide that are impermeable to moisture in the upper GI tract but dissolve or become permeable under the specific pH conditions of the distal colon, providing both protection and targeted release

Inventive Principle:

Principle #30Flexible shells and thin films

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These delayed release compositions achieve improved stability and targeted delivery of linaclotide to the lower GI tract, reducing adverse events like diarrhea while maintaining or enhancing the therapeutic efficacy for treating gastrointestinal disorders such as IBS-c, CIC, and abdominal pain.

Implementation Method 1

enteric-coated beads or tablets with pH-sensitive polymeric coatings

Methodology Applied

Scientific EffectpH-sensitive dissolution:

Data Source

PatentUS20250073301A1Delayed Release Compositions of Linaclotide

Publication Date: 2025.03.06 IRONWOOD PHARMACEUTICALS INC

AI summary

The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.